Massachusetts Financial Services Co. MA lessened its stake in TransMedics Group Inc (NASDAQ:TMDX) by 0.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 368,013 shares of the company’s stock after selling 1,374 shares during the quarter. Massachusetts Financial Services Co. MA owned about 1.74% of TransMedics Group worth $8,740,000 at the end of the most recent reporting period.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Several other large investors also recently bought and sold shares of the stock. NumerixS Investment Technologies Inc purchased a new position in TransMedics Group in the second quarter valued at $43,000. JPMorgan Chase & Co. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $50,000. Tower Research Capital LLC TRC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $190,000. Blackstone Group Inc purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $290,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $314,000. 65.84% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on TMDX. Cowen reduced their target price on TransMedics Group from $40.00 to $28.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Zacks Investment Research raised TransMedics Group from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. TransMedics Group currently has an average rating of “Buy” and a consensus price target of $33.00.
Shares of TMDX stock opened at $18.00 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.61 and a current ratio of 7.33. The stock’s 50-day moving average price is $18.05 and its 200 day moving average price is $23.44. TransMedics Group Inc has a 52-week low of $15.74 and a 52-week high of $31.54.
TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.67 million. As a group, equities research analysts anticipate that TransMedics Group Inc will post -2.09 EPS for the current year.
In other TransMedics Group news, Director David Weill bought 10,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $170,000.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $170,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
About TransMedics Group
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Featured Article: What is a Real Estate Investment Trust (REIT)?